The Center for Reproductive Rights on Wednesday asked a federal court to reopen its 2005 lawsuit against the Food and Drug Administration for imposing age restrictions on emergency contraceptive drugs.
"I am appalled that politics has once again trumped science," wrote Brooklyn College Health Clinic director and nurse practitioner Ilene Tannenbaum in a letter to the New York Times. That reaction summed up much of the medical community's response to the Department of Health and Human Services' overruling of the Food and Drug Administration's decision to make the Plan B contraceptive pill a full nonprescription product.
Food and Drug Administration commissioner Margaret Hamburg on Wednesday issued a public statement that the agency was prepared to approve Plan B as a nonprescription medication, but reversed that decision following a directive from the Department of Health and Human Services Wednesday morning.
The Food and Drug Administration will decide on Wednesday whether to remove merchandising restrictions on the emergency contraceptive Plan B and allow the product to be merchandised in the front-end without age restrictions, according to a report published Monday in the Washington Post.
A wave of patent expirations over the next several years will open up a broad swath of drugs to generic competition, and India's Lupin Pharmaceuticals is looking to benefit, according to published reports.
The Food and Drug Administration on Friday warned U.S. consumers not to use the emergency birth control medicine labeled as Evital, as it may be a counterfeit version of the “morning after pill” and may not be safe or effective in preventing pregnancy.